Prostate Cancer
Conditions
Keywords
Prostate Cancer Detection by Serum Proteomic Profiling
Brief summary
: Researchers would like to see if a new test called SELDI (Surface Enhanced Laser Desorption Ionization) analysis can predict biopsy results better than PSA tests.
Detailed description
A blood sample of approximately 30 cc will be collected prior to the patients standard of care radical prostatectomy surgery. This blood will be used for the SELDI analysis. The remainder of the blood sample will be stored and may be used for the PSA test at a later date. The patient will have a final blood draw 3 months to 1 year following surgery.
Interventions
None listed
Sponsors
University of California, Irvine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* For all subjects: * Men 50 years of age or older. * Serum PSA greater than or equal to 2.5 ng/ml and less then or equal to 10.0 ng/ml determined by a measurement within the past six months, and/or digital rectal exam suspicious for prostate cancer as determined by the patient's Urologist. * It has been determined by the treating physician that a prostate biopsy is clinically indicated. * Patients will have already been diagnosed with prostate cancer and scheduled for a radical prostatectomy. For study on treatment effect * Men with clinically localized prostate cancer (total PSA \< 20 ng/ml and clinical T2b or less). * Men with organ confined prostate cancer as determined by final pathologic diagnosis.
Exclusion criteria
*
Countries
United States
Outcome results
None listed